HRMAS 1H spectroscopy of the novel VEGF-RTK inhibitor AG013736 in a breast cancer model
Kurhanewicz J, Hylton N, Jarso S, Pallavicini M, Shalinsky D, Hu-Lowe D, Wilmes L
University of California San Francisco
High-resolution magic angle spinning (HRMAS) 1H spectroscopy was utilized to investigate the treatment effects of the novel vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), AG-013736, in a human breast cancer xenograft model. Tumor samples evaluated after 7 days of AG013736 treatment showed a 3.5-fold increase in total lipid and a 2-fold decrease in total choline compared to untreated controls. 2D TOCSY showed that phosphocholine, glycerophosphocholine and choline decreased in treated tumors. These metabolic changes may reflect treatment-induced necrosis or apoptosis. Previous studies have shown that AG013736 treatment inhibited tumor growth and decreased tumor endothelial transfer constant.